J Virol

• 

  Publication Venue For

  • Modulation of Sialic Acid Dependence Influences the Central Nervous System Transduction Profile of Adeno-associated Viruses..  93. 2019
  • Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models..  93. 2019
  • Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants..  93. 2019
  • Mapping and Engineering Functional Domains of the Assembly-Activating Protein of Adeno-associated Viruses..  92. 2018
  • Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination..  92. 2018
  • Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity..  91. 2017
  • Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses..  91. 2017
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies..  91. 2017
  • Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification..  90:11247-11258. 2016
  • Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice..  90:10209-10219. 2016
  • Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design..  90:5899-5914. 2016
  • Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site..  90:5219-5230. 2016
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds..  90:5031-5046. 2016
  • Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus..  90:4966-4980. 2016
  • A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies..  90:2127-2134. 2016
  • Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif..  89:10156-10175. 2015
  • Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research..  89:7478-7493. 2015
  • Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates..  89:8525-8539. 2015
  • Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection..  89:5895-5903. 2015
  • Unique glycan signatures regulate adeno-associated virus tropism in the developing brain..  89:3976-3987. 2015
  • Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo..  88:12669-12682. 2014
  • Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease..  88:11965-11972. 2014
  • Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains..  88:10767-10777. 2014
  • Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs..  88:8065-8076. 2014
  • Identification of novel, highly expressed retroviral microRNAs in cells infected by bovine foamy virus..  88:4679-4686. 2014
  • Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies..  88:2489-2507. 2014
  • Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity..  88:2633-2644. 2014
  • In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies..  87:8272-8281. 2013
  • Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design..  87:7218-7233. 2013
  • Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees..  87:7828-7836. 2013
  • Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk..  87:6986-6999. 2013
  • Mutational inactivation of herpes simplex virus 1 microRNAs identifies viral mRNA targets and reveals phenotypic effects in culture..  87:6589-6603. 2013
  • Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1..  87:4185-4201. 2013
  • Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion..  87:1554-1568. 2013
  • Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family..  86:11521-11532. 2012
  • A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies..  86:8319-8323. 2012
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages..  86:7496-7507. 2012
  • The development of CD4 binding site antibodies during HIV-1 infection..  86:7588-7595. 2012
  • Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication..  86:6835-6846. 2012
  • Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge..  86:4644-4657. 2012
  • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design..  86:4688-4692. 2012
  • Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0..  86:3112-3120. 2012
  • Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages..  86:2715-2728. 2012
  • High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection..  86:2153-2164. 2012
  • Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies..  85:11401-11408. 2011
  • Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation..  85:11725-11731. 2011
  • Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection..  85:11196-11207. 2011
  • Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals..  85:11502-11519. 2011
  • Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors..  85:9998-10009. 2011
  • Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection..  85:10518-10528. 2011
  • Primary infection by a human immunodeficiency virus with atypical coreceptor tropism..  85:10669-10681. 2011
  • HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies..  85:9555-9567. 2011
  • Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01..  85:8954-8967. 2011
  • Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins..  85:8514-8527. 2011
  • epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals..  85:9286-9299. 2011
  • Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry..  85:8270-8284. 2011
  • Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual..  85:7719-7729. 2011
  • An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum..  85:7029-7036. 2011
  • Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals..  85:3507-3516. 2011
  • Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens..  85:1340-1347. 2011
  • Wide variation in the multiplicity of HIV-1 infection among injection drug users..  84:6241-6247. 2010
  • Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia..  83:10677-10683. 2009
  • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants..  83:3556-3567. 2009
  • Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia..  82:12449-12463. 2008
  • Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens..  82:6869-6879. 2008
  • Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys..  82:5618-5630. 2008
  • Surface loop dynamics in adeno-associated virus capsid assembly..  82:5178-5189. 2008
  • Induction of Plasma (TRAIL), TNFR-2, Fas Ligand and Plasma Microparticles After HIV-1 Transmission: Implications for HIV-1 Vaccine Design. 2008
  • Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing..  82:3952-3970. 2008
  • Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection..  82:115-125. 2008
  • Translation by the adenovirus tripartite leader: elements which determine independence from cap-binding protein complex.  64:2669-2677. 1990